Literature DB >> 8281679

Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease. Endothelial function revisited.

H el-Tamimi1, M Mansour, T J Wargovich, J A Hill, R A Kerensky, C R Conti, C J Pepine.   

Abstract

BACKGROUND: In patients with angiographically detectable atherosclerosis or in those with risk factors for coronary artery disease, intracoronary acetylcholine causes coronary constriction instead of endothelium-derived relaxing factor-mediated dilation. Therefore, it has been hypothesized that diffuse endothelial dysfunction precedes development of coronary atherosclerosis. We tested this hypothesis in a systematic investigation of the effects of ascending doses of acetylcholine on the diameters of nonstenotic segments of the left coronary artery in patients with advanced atherosclerosis and coronary risk factors. METHODS AND
RESULTS: Effects of intracoronary infusion of acetylcholine (10(-6) to 10(-4) mol/L) on diameters of proximal, middle, and distal nonstenotic segments of the left coronary artery were studied in 28 consecutive patients with chronic stable angina, positive exercise tests, and angiographic evidence of obstructive atherosclerosis (> or = 50% reduction in lumen diameter in at least one vessel). Two patterns of response to the maximal acetylcholine dose (10(-4) mol/L) were observed. In 21 patients (group 1), only constriction was observed in all left anterior descending and circumflex artery segments studied (16 +/- 3%, 19 +/- 4%, and 23 +/- 4%, respectively; P < .01 compared with control). In 7 other patients (group 2), both constriction and dilation were observed in adjacent segments of the same vessel; maximal acetylcholine dose caused constriction in 14 left anterior descending artery segments from a control diameter of 1.94 +/- 0.19 to 1.33 +/- 0.26 mm (37% reduction, P < .01) and dilation in 16 other segments from 1.63 +/- 0.22 to 1.93 +/- 0.21 mm (25% increase, P < .01). In the circumflex artery, this dose caused constriction in 16 segments from a control diameter of 1.88 +/- 0.14 to 1.33 +/- 0.17 mm (31% reduction, P < .01) and dilation in 12 segments from 1.37 +/- 0.12 to 1.71 +/- 0.09 mm (34% increase, P < .01).
CONCLUSIONS: In 25% of patients studied with advanced angiographic coronary atherosclerosis and coronary risk factors, coronary segments with acetylcholine-inducible dilatation are present. In these patients, the endothelium is not diffusely dysfunctional as currently believed but rather shows marked segmental heterogeneity in the response to acetylcholine reflecting degrees of endothelial dysfunction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8281679     DOI: 10.1161/01.cir.89.1.45

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

1.  Increased coronary vasoconstrictor response to acetylcholine in women with chest pain and normal coronary arteriograms (cardiac syndrome X).

Authors:  Peter Ong; Anastasios Athanasiadis; Heiko Mahrholdt; Gabor Borgulya; Udo Sechtem; Juan Carlos Kaski
Journal:  Clin Res Cardiol       Date:  2012-03-10       Impact factor: 5.460

2.  Assessing progression or regression of CAD: the role of perfusion imaging.

Authors:  K Lance Gould
Journal:  J Nucl Cardiol       Date:  2005 Nov-Dec       Impact factor: 5.952

Review 3.  Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.

Authors:  Christine R Culy; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Calpain inhibition decreases myocardial apoptosis in a swine model of chronic myocardial ischemia.

Authors:  Brittany A Potz; Ashraf A Sabe; Nassrene Y Elmadhun; Jun Feng; Yuhong Liu; Hunter Mitchell; Peter Quesenberry; M Ruhul Abid; Frank W Sellke
Journal:  Surgery       Date:  2015-05-16       Impact factor: 3.982

Review 5.  Novel functional risk factors for the prediction of cardiovascular events in vulnerable patients following acute coronary syndrome.

Authors:  Martin K Reriani; Andreas J Flammer; Abdi Jama; Lilach O Lerman; Amir Lerman
Journal:  Circ J       Date:  2012       Impact factor: 2.993

6.  Coronary atheroma composition and its association with segmental endothelial dysfunction in non-ST segment elevation myocardial infarction: novel insights with radiofrequency (iMAP) intravascular ultrasonography.

Authors:  Rishi Puri; Stephen J Nicholls; Danielle M Brennan; Jordan Andrews; Gary Y Liew; Angelo Carbone; Barbara Copus; Adam J Nelson; Samir R Kapadia; E Murat Tuzcu; John F Beltrame; Stephen G Worthley; Matthew I Worthley
Journal:  Int J Cardiovasc Imaging       Date:  2014-10-09       Impact factor: 2.357

7.  Assessment of vasoreactivity using videodensitometry coronary angiography.

Authors:  Sabee Molloi; Gholam R Berenji; Trien T Dang; Ghassan Kassab
Journal:  Int J Cardiovasc Imaging       Date:  2003-08       Impact factor: 2.357

8.  Strong Relationship Between Vascular Function in the Coronary and Brachial Arteries.

Authors:  Ryan M Broxterman; Melissa A Witman; Joel D Trinity; H Jonathan Groot; Matthew J Rossman; Song-Young Park; Simon Malenfant; Jayson R Gifford; Oh Sung Kwon; Soung Hun Park; Catherine L Jarrett; Katherine L Shields; Jay R Hydren; Angela V Bisconti; Theophilus Owan; Anu Abraham; Anwar Tandar; Charles Y Lui; Brigham R Smith; Russell S Richardson
Journal:  Hypertension       Date:  2019-05-06       Impact factor: 10.190

9.  Segmental coronary endothelial dysfunction in patients with minimal atherosclerosis is associated with necrotic core plaques.

Authors:  S Lavi; J-H Bae; C S Rihal; A Prasad; G W Barsness; R J Lennon; D R Holmes; A Lerman
Journal:  Heart       Date:  2009-06-03       Impact factor: 5.994

Review 10.  The assessment of endothelial function: from research into clinical practice.

Authors:  Andreas J Flammer; Todd Anderson; David S Celermajer; Mark A Creager; John Deanfield; Peter Ganz; Naomi M Hamburg; Thomas F Lüscher; Michael Shechter; Stefano Taddei; Joseph A Vita; Amir Lerman
Journal:  Circulation       Date:  2012-08-07       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.